A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers

PHASE3TerminatedINTERVENTIONAL
Enrollment

461

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Stomach UlcerDuodenal Ulcer
Interventions
DRUG

Lansoprazole

Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.

DRUG

Gefarnate

Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.

Trial Locations (65)

Unknown

Matsudo-shi

Yotsukaido-shi

Imabari

Matsuyama

Fukui-shi

Fukuoka

Onga-gun

Gifu

Fujioka-shi

Maebashi

Higashihiroshima-shi

Hiroshima

Kure-shi

Asahikawa-shi

Hakodate-shi

Sapporo

Nishinomiya-shi

Higashiibaraki-gun

Hitachi-Naka

Inashiki-gun

Namegata-shi

Tsuchiura-shi

Yuuki-shi

Hakusan-shi

Kanazawa

Komatsu-shi

Takamatsu

Fujisawa-shi

Kawasaki-shi

Yamato-shi

Yokohama

Yokosuka-shi

Kochi

Kumamoto

Kyoto

Matsusaka-shi

Shima-shi

Tsu

Sendai

Ebino-shi

Miyazaki

Jōetsu

Niigata

Beppu-shi

Ōita

Ibaraki-shi

Matsubara-shi

Osaka

Takatsuki-shi

Hanyuu-shi

Ōtsu

Hamada-shi

Sunto-gun

Shimotsuke-shi

Chiyoda-ku

Chuuo-ku

Hachioji-shi

Kiyose-shi

Minato-ku

Shinagawa-ku

Shinjuku-ku

Toshima-ku

Higashitagawa-gun

Iwakuni-shi

Shimonoseki-shi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY